Betanis, Tradjenta and Onbrez priced and set for launch in Japan
This article was originally published in Scrip
Executive Summary
Astellas' first-in-class overactive bladder therapy Betanis (mirabegron) has received a price in Japan and will be included in the national reimbursement tariff on 12 September, clearing the way for its first launch worldwide.